




PhD in Pharmacology and Toxicology - University of Padua  
PhD in Therapeutical Approaches in Oncology - University of Strasbourg  
Callerio Foundation Onlus - Trieste  
INSERM U682 - Strasbourg



# A novel mechanism of action of RDC11: targeting HIF-1 and mTOR pathways

PhD candidate  
**Vania Vidimar**

Supervisor  
**Christian Gaiddon**

5<sup>eme</sup> Canceropole du Grand Est  
Strasbourg, 3<sup>rd</sup> November 2011

METAL-BASED  
CHEMOTHERAPY

CISPLATIN

- Poor selectivity
- Severe side effects
- Drug-resistance phenomena




New platinum-free  
metal-based drugs

RDC11

Synthesized by Prof M. Pfeffer  
Unit UMR 7177 (Strasbourg)

RUTHENIUM-DERIVED  
COMPOUNDS (RDCs)

RUTHENIUM  
DERIVATES




- Interesting anticancer properties *in vivo* and *in vitro*
- No strict correlation between DNA interaction and its activity

ALTERNATIVE MODES  
OF ACTION

# INVESTIGATE THE MOLECULAR BASIS OF RDC11 EFFECTIVENESS IN TREATING CANCER



Search for RDC11 direct targets in order to improve its selectivity against cancer cells



*Affimatrix* MICROARRAY




New RDC11-regulated genes





HIF-1 and mTOR pathways

Effect of RDC11 on HIF-1 $\alpha$  protein and gene expression




RDC11, cisplatin 5 $\mu$ M corresponding to IC<sub>50</sub>



Partial reversion of HIF-1 $\alpha$



Proteasome in part involved in HIF-1 $\alpha$  degradation





RDC11 decreases HIF-1 $\alpha$  protein expression mainly by reducing HIF-1 $\alpha$  mRNA level

HIF-1 $\alpha$


ANGIOGENESIS

GLUCOSE METABOLISM





One-way ANOVA + Tukey-Kramer post-test vs corresponding control:  
 \*\*\* = p<0.001; \*\* = p<0.01

RDC11 reduces *VEGF* and *GLUT-1* mRNA levels




Phosphorylation of the ribosomal protein S6 by S6 kinase is a crucial step in HIF-1 $\alpha$  protein synthesis




Akt activation by mTOR: most frequent alteration in human cancers

RDC11 reduces S6-P and Akt-P expression



## RDC11 affects specific components of HIF-1 and mTOR pathways



**UNIQUE CHARACTERISTIC FOR AN  
ORGANOMETALLIC COMPOUND**



**Targeted therapy**

**THE MAIN CHALLENGE OF CANCER CHEMOTHERAPY TODAY**



# ACKNOWLEDGEMENTS



INSERM U682 - Strasbourg  
Group "Molecular mechanisms of the stress response and pathologies"

Dr. Christian Gaiddon



UMR 7177  
Laboratoire de Synthèses Métallo-Induites

Prof. Michel Pfeffer



Callerio Foundation Onlus - Trieste

Prof. Gianni Sava  
Dr. Alberta Bergamo

Thank you for your attention